Asprius Lifesciences’ Miracle Drug Could End Diabetic Neuropathy Suffering!
Exciting News for Biotech Grads! Asprius Lifesciences, a pharmaceutical company in Gujarat, has made a significant breakthrough in treating Diabetic Neuropathy. This condition damages nerves in the body’s outer areas and affects over 2% of people worldwide.
The company has already filed a patent for their innovative Fixed-Dose Combination (FDC) treatment. This new drug shows great promise in addressing peripheral neuropathy, a common problem faced by many.
Vishal Zinzuwadia, the Chairman and Managing Director of Asprius Lifesciences, expressed their dedication to creating groundbreaking medicines. The goal is to help doctors provide better care to patients, especially when traditional treatments fall short.
The drug aims to promote early nerve regeneration and reduce the impact of Diabetic Neuropathy. It targets medical conditions that increase neuropathy risk and introduces neuro-protective medications.
Dr. Sanjay Agrawal, the company’s medical director, stressed the urgency of addressing Diabetic Neuropathy in India. With an estimated 77 million adults affected by diabetes (expected to reach 101.2 million by 2030), it’s crucial to find effective solutions. Type 2 diabetes, linked to lifestyle factors like poor diet and inactivity, is the most common type in India.
Dr. Agrawal, the inventor of this
formulation, highlighted that Diabetic Neuropathy can damage specific parts of the nervous system, making it essential to find a reliable treatment.This medicine offers hope to millions suffering from Diabetic Neuropathy, alleviating symptoms like weakness, numbness, and severe pain in the hands and feet. Asprius Lifesciences’ discovery could change the lives of countless individuals facing this challenging condition. Stay tuned for more updates on this groundbreaking development!
